Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

It is justified to use distal protection filter in venous bridges?

The current guidelines point out a class I recommendation to the use of distal embolic protection devices for angioplasty in venous bridges, in fact, the evidence is controversial to support this recommendation.

¿Se justifica utilizar filtro de protección distal en los puentes venosos?

The goal of this meta-analysis was to compare mortality from any cause, major cardiovascular events, acute myocardial infarction, and target vessel revascularization of interventions on saphenous venous bridges with or without distal protection systems.


Read also: Angioplasty vs. Surgery in Long-Term Critical Ischemia”.


A total of 8 studies were analyzed with the incredible number of 52893 patients who compared angioplasty in venous bridges with distal protection system (n = 11506) and without embolic protection (n = 41387).

 

There were no significant differences in mortality from any cause (OR 0.79, TI 95% 0.55 -1.12; p = 0.19), major adverse cardiovascular events (OR 0.73, TI 95% 0.51 -1.05; p = 0.09), revascularization of the target lesion (OR 1.0, TI 95% 0.95 -1.05, p = 0.94), periprocedural myocardial Infarction (OR 1.12, TI 95% 0.65 -1.90, p = 0.69) or infarction at follow-up (OR 0.80, TI 95% CI 0.52 -1.23; p = 0.30) between the two groups.


Read also: The 10 Commandments of ESC’s New STEMI Guidelines”.


A sensitivity analysis excluding the CathPCI registry did not show differences in terms of periprocedural myocardial Infarction or revascularization, but a lower mortality and combined events. The analyzes, including only the observational studies, did not show significant differences in any of the aforementioned points.

 

Conclusion

This work, which included more than 50,000 patients, suggests that there is no apparent benefit in the routine use of distal embolic protection systems when angioplasty is performed on venous bridges in contemporary real-world interventions. Obviously, randomized studies are necessary to define the topic and, in the meantime, review the current recommendations of the guidelines.

 

Editorial comment

Surprisingly, when a fixed effect model was used, it was observed that the use of distal embolic protection systems was associated with an increase of 1.5 times the risk of periprocedural myocardial Infarction (p <0.0001). This is exactly the opposite of what was expected, since the main goal of the filters should be to prevent the “no reflow” and the consequent infarction. Here is the reason for all the questions and the reason to continue investigating.

 

The CathPCI Registry has the largest number of patients and could have biased itself, the results of this meta-analysis. That is why in the sensitivity analysis the mentioned work was excluded, observing a clear homogeneity of all the events.

 

Original title: Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device. A Comprehensive Review and Meta-Analysis.

Reference: Timir K. Paul et al. Circ Cardiovasc Interv. 2017 Dec; 10(12).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

 

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...